Lung Cancer Clinical Trials
G1T28 (CDK 4/6 inhibitor) in combination with Etoposide and Carboplatin in extensive stage small cell lung cancer. Click here to learn more.
A Phase III study of MPDL3280A (anti-PD-L1 antibody) in combination with Carboplatin + Nab-Paclitaxel in patients with non-squamous non small cell lung cancer [IMpower 130]. Click here to learn more.
A Phase III study of MPDL3280A (Anti-PD-L1) in combination with Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel compared with Carboplatin + Nab-paclitaxel in patients with Stage IV squamous non small cell lung cancer (NSCLC) [IMpower 131]. Click here to learn more.
Safety and efficacy study of Nab®-Paclitaxel with CC-486 and Nab®-Paclitaxel monotherapy as second-line treatment for advanced nonsquamous non small cell lung cancer. Click here to learn more.
Study of G1T28 in patients with previously treated extensive stage SCLC receiving Topotecan chemotherapy. Click here to learn more.
Safety and efficacy study of Abraxane as maintenance treatment after Abraxane Plus Carboplatin in first-line Stage IIIB / IV squamous cell non small cell lung cancer. Click here to learn more.
S1400 biomarker-targeted second-line therapy in treating patients with recurrent Stage IIIB-IV squamous cell lung cancer. Click here to learn more.
A randomized Phase III study comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel Avastin with or without concurrent Cetuximab in patients with advanced non small cell lung cancer.
A randomized Phase III study of LY2835219 plus best supportive care versus erlotinib plus best supportive care in patients with Stage IV NSCLC with a detectable KRAS mutation who have progressed after platinum-based chemotherapy
A Phase III, open-label, randomized, multi-center, international study of MEDI4736 vs standard of care in patients with locally advanced or metastatic non small cell lung cancer (Stage IIIB-IV) who have received at least two prior systemic treatment regimens including one platinum-based chemotherapy regimen and do not have known EGFR TK activating mutations or ALK rearrangements.
A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer. Click here to learn more.
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK). Click here to learn more.
A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA). Click here to learn more.
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements. Click here to learn more.
A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks. Click here to learn more.
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370). Click here to learn more.
A Phase II Single-arm Trial to Investigate Tepotinib in Stage IIIB/IV Adenocarcinoma of the Lung With MET Exon 14 (METex14) Skipping Alterations After Failure of at Least One Prior Active Therapy, Including a Platinum-doublet-containing Regimen. Click here to learn more.
Phase 2, Parallel-Arm Study of MGCD265 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor. Click here to learn more.
A Phase Ib Study of the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Patients With Multiple Myeloma (Relapsed/Refractory and Post-Autologous Stem Cell Transplantation). Click here to learn more.
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients. Click here to learn more.